KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.
A molecular mechanism by which KLF4 governs AML progression is revealed, providing a novel therapeutic target and a potential small-molecule inhibitor for AML treatment.